1 Table of Contents

1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 5

2 Introduction 6
2.1 Insulin Pens Overview 6

3 Products under Development 7
3.1 Insulin Pens - Pipeline Products by Stage of Development 7
3.2 Insulin Pens - Pipeline Products by Segment 8
3.3 Insulin Pens - Pipeline Products by Territory 9
3.4 Insulin Pens - Pipeline Products by Regulatory Path 10
3.5 Insulin Pens - Pipeline Products by Estimated Approval Date 11

4 Insulin Pens - Pipeline Products under Development by Companies 12
4.1 Insulin Pens Companies - Pipeline Products by Stage of Development 12
4.2 Insulin Pens - Pipeline Products by Stage of Development 13

5 Insulin Pens Companies and Product Overview 14
5.1 Becton, Dickinson and Company Company Overview 14
5.1.1 Becton, Dickinson and Company Pipeline Products & Ongoing Clinical Trials Overview 14
5.2 Calibra Medical, Inc. Company Overview 16
5.2.1 Calibra Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 16
5.3 Cambridge Consultants Limited Company Overview 17
5.3.1 Cambridge Consultants Limited Pipeline Products & Ongoing Clinical Trials Overview 17
5.4 Companion Medical, Inc. Company Overview 19
5.4.1 Companion Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 19
5.5 Emperra GmbH E-Health Technologies Company Overview 20
5.5.1 Emperra GmbH E-Health Technologies Pipeline Products & Ongoing Clinical Trials Overview 20
5.6 MedPro Safety Products, Inc. Company Overview 22
5.6.1 MedPro Safety Products, Inc. Pipeline Products & Ongoing Clinical Trials Overview 22
5.7 MicroPort Scientific Corporation Company Overview 23
5.7.1 MicroPort Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview 23
5.8 Sanofi Company Overview 25
5.8.1 Sanofi Pipeline Products & Ongoing Clinical Trials Overview 25

6 Insulin Pens- Recent Developments 27
6.1 Mar 23, 2016: B. Braun’s growth trend continues 27
6.2 Mar 10, 2016: Sanofi Appoints Dr. Ameet thwani to Executive Committee and Executive Vice President, Group Chief Medical Officer 28
6.3 Mar 08, 2016: Antares Pharma Reports Fourth Quarter and Full Year 2015 Operating and Fincial Results 28
6.4 Mar 07, 2016: InsuLine Medical to Raise Funds in Fincing Round 30
6.5 Feb 09, 2016: Sanofi Delivered 2015 Business EPS Up 8.5% On A Reported Basis And Stable At Constant Exchange Rates Consistent With Guidance 30
6.6 Feb 04, 2016: Sanofi India Announces Results for the Quarter & Year Ended December 31, 2015 38
6.7 Feb 03, 2016: BD Announces Results For 2016 First Fiscal Quarter 38
6.8 Jan 26, 2016: Antares Pharma Announces CEO Transition 39
6.9 Jan 21, 2016: U.S. Food and Drug Administration Approves Humulin R U-500 KwikPen 40
6.10 Jan 21, 2016: Singularity University and BD Announce Collaboration Dedicated to Address Global Healthcare Challenges 40
6.11 Jan 21, 2016: Biocon Q3FY16 Net Profit Up 13% at Rs 103 Crore, EBITDA Increases 23% to Rs 209 Crore, Revenues at Rs 857 Crore, up by 10% 41
6.12 Jan 11, 2016: Insulet Enters into Co-Development Agreement with Eli Lilly 44
6.13 Jan 05, 2016: Ypsomed Enters into Distribution Agreement with Tonghua Dongbao Pharma 44
6.14 Dec 04, 2015: Change in B. Braun Magement Board 44
6.15 Dec 01, 2015: Owen Mumford Launches New Touch Activated Lancet 44
6.16 Nov 20, 2015: Sanofi India Announces Sale of Building in Andheri, Mumbai 45
6.17 Nov 05, 2015: Antares Pharma Reports Third Quarter 2015 Operating and Fincial Results 45
6.18 Nov 04, 2015: BD Announces Results For 2015 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2016 Guidance 46
6.19 Oct 20, 2015: Sanofi India - Outcome of Board Meeting 48
6.20 Oct 20, 2015: Sanofi India Announces Q3 results & Limited Review Report for the quarter ended September 30, 2015 48
6.21 Sep 22, 2015: Novo Nordisk and the Food and Drug Administration of the Islamic Republic of Iran sign memorandum of understanding to build manufacturing facility in Iran 48
6.22 Sep 16, 2015: Sanofi’s CSR Achievements Recognized In The Dow Jones Sustaibility Indices 49
6.23 Sep 15, 2015: Biocon Iugurates World Class Devices Facility & Introduces Basalog One 49
6.24 Sep 15, 2015: Sanofi Prices Public Offering of Notes Due 2019 for USD850 Million 50
6.25 Sep 15, 2015: Sanofi Prices Public Offering of 1.5% Notes Due 2025 for USD850 Million 50
6.26 Sep 15, 2015: BD med 2015 Outstanding Corporate Innovator Winner by Product Development and Magement Association 50
6.27 Sep 15, 2015: Biocon Iugurates World Class Devices Facility 51
6.28 Aug 24, 2015: Biocon Clarifies On FDA’s Inspection 51
6.29 Aug 18, 2015: Lilly’s Humalog 200 units/mL KwikPen Now Available in U.S. Pharmacies 51
6.30 Aug 10, 2015: Antares Pharma Reports Second Quarter 2015 Operating and Fincial Results 52
6.31 Aug 06, 2015: BD Announces Results for 2015 Third Fiscal Quarter and Raises EPS Guidance for Fiscal 2015 53
6.32 Jul 30, 2015: Sanofi delivers solid sales and business EPS(1) growth in Q2 2015 55
6.33 Jul 23, 2015: Biocon’s Earnings Surge in Q1 FY16; Revenue up by 15% at Rs. 857 Crore, Net Profit up by 23% at Rs. 126 Crore 62
6.34 Jul 23, 2015: Appointment of Chief Fincial Officer : Sanofi India 63
6.35 Jul 21, 2015: Sanofi India Announces Q2 results 63
6.36 Jul 15, 2015: Sanofi Announces New, Global Business Unit Structure To Drive Future Growth 64
6.37 Jul 15, 2015: BD Opens Advance Diabetes Care Headquarters in Andover, Mass. 64
6.38 Jul 14, 2015: Antares Pharma Appoints Peter J. Graham Esq., Senior Vice President, General Counsel, Human Resources, Chief Compliance Officer and Corporate Secretary 65
6.39 Jul 13, 2015: BD Announces Sustaibility Goals for 2020 65
6.40 Jul 09, 2015: Gerresheimer substantially improves operating earnings in second quarter 66
6.41 Jul 08, 2015: BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 67
6.42 Jul 01, 2015: Haselmeier Group Announces the Extension and Reorganization of its Executive Board 67
6.43 Jun 30, 2015: Ypsomed now supplies the YpsoPen in Poland 68
6.44 Jun 24, 2015: EMPERRA’s Bluetooth-ebled ESYSTA Smart Insulin Pen in the Last Stages of the CE Approval Process 68
6.45 Jun 06, 2015: New Clinical Data Suggest Infusion Set with BD FlowSmart Technology May Improve Insulin Flow and Reduce Silent Occlusions 70
6.46 Jun 02, 2015: BD Participates in White House Forum on Antibiotic Stewardship 71
6.47 May 27, 2015: U.S. Food and Drug Administration Approves Humalog 200 units/mL KwikPen 71
6.48 May 21, 2015: Haselmeier receives prestigious accolade for two of their products: The intertiol GOOD DESIGN Award 2014 72
6.49 May 20, 2015: Companion Medical Raises USD3.15 Million in Series B Fincing 72
6.50 May 18, 2015: Haselmeier Group Announces the Relocation of Haselmeier in the United States 73
6.51 May 15, 2015: Sanofi Announces Departure Of Chief Strategy Officer 73
6.52 May 13, 2015: DuBiotech Welcomes Germany’s B.Braun 73
6.53 May 11, 2015: Antares Pharma Reports First Quarter 2015 Operating and Fincial Results 74
6.54 May 11, 2015: Antares Pharma Reports First Quarter 2015 Fincial and Operating Results 75
6.55 May 07, 2015: BD Announces Results For 2015 Second Fiscal Quarter 77
6.56 May 07, 2015: Biocon-Mylan Programs Make Progress: PEG-G-CSF and Adalimumab enter Phase 3 clinical trials; Patient recruitment for one Insulin Glargine Phase 3 study completed 78
7 Appendix 79
7.1 Methodology 79
7.2 About GlobalData 81
7.3 Contact Us 82
7.4 Disclaimer 82